195 related articles for article (PubMed ID: 21149670)
1. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.
Ocaña A; Amir E; Vera F; Eisenhauer EA; Tannock IF
J Clin Oncol; 2011 Jan; 29(3):254-6. PubMed ID: 21149670
[No Abstract] [Full Text] [Related]
2. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
Lorusso PM; Boerner SA; Hunsberger S
J Clin Oncol; 2011 Aug; 29(22):2952-5. PubMed ID: 21709201
[No Abstract] [Full Text] [Related]
3. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
4. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Los M; Roodhart JM; Voest EE
Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in the treatment of metastatic colorectal cancer.
Caprioni F; Fornarini G
Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in colorectal carcinoma: more than a theory.
Pickering L; Rudman S; Ross PJ; Leslie MD
Colorectal Dis; 2008 Mar; 10(3):209-18; discussion 218-221. PubMed ID: 18257846
[TBL] [Abstract][Full Text] [Related]
7. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Ferrara N; Hillan KJ; Gerber HP; Novotny W
Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787
[No Abstract] [Full Text] [Related]
8. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
Wilkes GM
Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):54-6. PubMed ID: 19856612
[No Abstract] [Full Text] [Related]
10. [Angiogenesis and breast cancer].
Bachelot T; Ray-Coquard I; Cassier P; Blay JY
Bull Cancer; 2007 Jul; 94 Spec No():S203-10. PubMed ID: 17846006
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of angiogenesis by proteins, peptides and "small molecules"].
Jayson G; Armand JP; Berdel WE
Onkologie; 2005 Oct; 28 Suppl 4():29-34. PubMed ID: 16205103
[No Abstract] [Full Text] [Related]
12. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
13. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
14. Technology evaluation: bevacizumab, Genentech/Roche.
Salgaller ML
Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
[TBL] [Abstract][Full Text] [Related]
15. The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer.
Banerjee S
Steroids; 2011 Jul; 76(8):807-11. PubMed ID: 21439993
[TBL] [Abstract][Full Text] [Related]
16. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Marty M; Pivot X
Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab: a new way of doing business?
Canning C; Lotery A
Eye (Lond); 2006 Sep; 20(9):985-7. PubMed ID: 16858443
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab: one treatment for all the seasons?
Gelibter AJ; Di Segni S; Zeuli M; Cognetti F
J Clin Oncol; 2008 Jan; 26(3):511; author reply 511-2. PubMed ID: 18202430
[No Abstract] [Full Text] [Related]
19. Mixed news for Avastin.
Mack GS
Nat Biotechnol; 2009 Jun; 27(6):494. PubMed ID: 19513035
[No Abstract] [Full Text] [Related]
20. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
